Maximum quantity allowed is 999
请选择数量
CAS RN: 73590-58-6 | 产品编码: O0359
Omeprazole
×
![]()
×
技术规格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
物性（参考值）
| 熔点 | 151 °C(dec.) |
| 水溶性 | 不溶 |
| 溶解性（微溶于） | 乙醇, 甲醇 |
| 溶解性（不溶于） | 乙醚 |
GHS
相关法规
| RTECS# | DD9087000 |
运输信息
| HS编码* | 2933.39-000 |
应用
Exosome research
Reference
- Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs
应用
最初に開発されたプロトンポンプ阻害剤 (PPI)，オメプラゾール
Omeprazole is the first proton pump inhibitor (PPI) that reduces gastric acid secretion. PPIs, such as omeprazole, lansoprazole [L0233], rabeprazole [R0115] and pantoprazole, are metabolized by cytochrome P 450 isoenzymes, 2C19 (CYP2C19) in the liver. The active (S)-enantiomer of omeprazole is esomeprazole. In additon, combinations of omeprazole as a PPI, amoxicillin [A2099], clarithromycin [C2220] and metronidazole [M0924] or another antibiotic have been reported to be effective in the treatment of Helicobacter pylori infection. Omeprazole is synthesized by the oxidation of omeprazole sulfide [O0437].
References
- Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome
- Omeprazole: the first proton pump inhibitor (a review)
- Omeprazole A review of its use in Helicobacter pylori infection, gastro-esophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs
- A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole (a review)
- Pharmacogenomics of proton pump inhibitors (a review)
参考文献
TCIMail
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。